---
author: mike
pubDatetime: 2024-05-02 19:38:22.086000
modDatetime: 
title: Q324 TECH earnings
slug: q324-tech-earnings
featured: false
ogImage: /assets/images/250_250.png
tags:
  - transcripts
  - earnings
  - healthcare
description: Earnings summary for Bio-Techne
---
### Earnings Results
- **Organic Revenue Growth:** Achieved 2% year-over-year organic revenue growth.
- **Adjusted Operating Margin:** Increased sequentially by 290 basis points to 33%.
- **Quarterly Revenue:** $303.4 million, a 3% increase on a reported basis, with acquisitions contributing 1% to reported growth.
- **Adjusted EPS:** $0.48 compared to $0.53 in the prior year quarter.
- **GAAP EPS:** $0.31 compared to $0.43 in the prior year.
- **Adjusted Gross Margin:** 71.9%, slightly lower than the 72.6% in the same quarter of the prior year.
- **Operating Margin for Protein Sciences Segment:** 44.2%, a decrease of 90 basis points year-over-year.
- **Diagnostics and Genomics Segment Revenue:** $87.5 million, with reported growth increasing 16% compared to the same quarter last year and organic revenue growth up 10%.

### Future Guidance
- **Q4 Expectations:** Expecting a performance similar to Q3 with stable markets, especially in the biotech end market and the China region.
- **Incremental Revenue and Margin Improvement:** Anticipating incremental sequential improvement in revenue and adjusted operating margins in Q4 relative to Q3.
- **Monitoring for FY25 Outlook:** Closely watching the impact of recent increases in biotech funding and Chinese government stimulus for fiscal year 2025 outlook and operating plans.

### Trends, Market Conditions, Sentiment
- **Market Stabilization:** Indications of biopharma end markets and the China region stabilizing with early signs that markets will improve in the second half of the calendar year.
- **Challenge in China:** Recognizing that the path back to accelerated growth in China may take longer than previous cycles but confirming stabilization of the business there.
- **Growth Pillars Performance:** Notably strong performance in cell and gene therapy, proteomic analysis solutions, spatial biology technology, and liquid biopsy platform.
- **Cost Management and Structural Alignments:** Ongoing focus on profitability through efficiency drives across the organization while investing for future growth.
- **Future Growth Enablers:** Monitoring biotech funding recovery and Chinese government's economic stimulus plans as key factors that could drive future revenue growth.

### Notable Quotes
- _"I'm pleased to report that our third quarter outperformed our initial expectations..."_ - Kim Kelderman, President and CEO.
- _"These growth pillars enabled by our leading portfolio of proteomic reagents and assays remain and clearly well positioned to enable our customers to improve the quality of life..."_ - Kim Kelderman.
- _"It appears as though the worst of the China slowdown is behind us at this point."_
- _"M&A remains a top priority for capital allocation."_ - James Hippel, CFO.
- _"...expect that gap in our performance relative to the market to be at least the same, if not better."_ - James Hippel on future growth relative to the market.
